Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial

INTRODUCTION: New HIV prevention strategies are urgently required. The discovery of broadly neutralising antibodies (bNAbs) has provided the opportunity to evaluate passive immunisation as a potential prevention strategy and facilitate vaccine development. Since 2014, several bNAbs have been isolate...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahomed, Sharana, Garrett, Nigel, Karim, Quarraisha A, Zuma, Nonhlanhla Y, Capparelli, Edmund, Baxter, Cheryl, Gengiah, Tanuja, Archary, Derseree, Samsunder, Natasha, Doria-Rose, Nicole, Moore, Penny, Williamson, Carolyn, Barouch, Dan H, Fast, Patricia E, Pozzetto, Bruno, Hankins, Catherine, Carlton, Kevin, Ledgerwood, Julie, Morris, Lynn, Mascola, John, Abdool Karim, Salim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
HIV/AIDS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692975/
https://www.ncbi.nlm.nih.gov/pubmed/33243815
http://dx.doi.org/10.1136/bmjopen-2020-042247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692975/
https://www.ncbi.nlm.nih.gov/pubmed/33243815
http://dx.doi.org/10.1136/bmjopen-2020-042247

Ejemplares similares